0OIR Release Date Of Nine-month Interim Report (Q3) 2021 For Alk And Audio Cast
05 November 2021 - 9:22PM
UK Regulatory
TIDMALK TIDMB
On Thursday, 11 November 2021, ALK (ALKB:DC / OMX: ALK B / AKABY
/ AKBLF) releases its nine-month interim report (Q3) 2021.
ALK will host a meeting for analysts and institutional investors
that day at 1.30pm (CET) at which Management will review the
financial results, the outlook and answer questions.
The meeting will be audio cast live on our website
https://ir.alk.net, where the related presentation will be
available shortly before the meeting begins.
Participants in the conference call are kindly requested to call
in before 1.25pm (CET). Danish participants should call in on tel.
+45 3544 5577 and international participants should call in on tel.
+44 333 300 0804 or +1 631 913 1422. Please use the following
participant pin code: 25705608#
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile
+45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on
allergy and allergic asthma. It markets allergy immunotherapy
treatments and other products and services for people with allergy
and allergy doctors. Headquartered in Hørsholm, Denmark, ALK
employs around 2,500 people worldwide and is listed on Nasdaq
Copenhagen. Find more information at www.alk.net.
Attachment
-- InvestorNews_05Nov21
https://ml-eu.globenewswire.com/Resource/Download/1c047004-7a51-4f6c-8801-a979506d0157
(END) Dow Jones Newswires
November 05, 2021 06:22 ET (10:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkemy Capital Investments (LSE:ALK)
Historical Stock Chart
From Apr 2023 to Apr 2024